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ABSTRACT
The SwissBioisostere database (http://www.
swissbioisostere.ch) contains information on mo-
lecular replacements and their performance in bio-
chemical assays. It is meant to provide researchers
in drug discovery projects with ideas for bioisosteric
modifications of their current lead molecule, as well
as to give interested scientists access to the details
on particular molecular replacements. As of August
2012, the database contains 21 293 355 datapoints
corresponding to 5 586 462 unique replacements
that have been measured in 35 039 assays against
1948 molecular targets representing 30 target
classes. The accessible data were created through
detection of matched molecular pairs and mining
bioactivity data in the ChEMBL database. The
SwissBioisostere database is hosted by the Swiss
Institute of Bioinformatics and available via a
web-based interface.
INTRODUCTION
During the course of drug discovery, a considerable
amount of time is spent in lead optimization (1). In this
phase, compounds that have been identiﬁed as active
against a molecularly deﬁned target of interest are
modiﬁed to carefully balance potency and other relevant
parameters, such as bioavailability, toxicity, metabolic
stability or solubility. Issues with any of these parameters
usually need to be addressed without losing the achieved
bioactivity against the primary target. The knowledge of
potential bioisosteres, i.e. pairs of replacements that share
physical and chemical similarities, can be of great help to
prioritize the synthesis of analogues with the purpose of
modulating the biological and biophysical properties of
the entire compound. Traditionally, these replacements
have been identiﬁed by simple chemical considerations
and trial-and-error and found their way into the
common knowledge of medicinal chemists over time.
Already in 1919, the concept of isosterism, i.e. molecules
or ions that possess the same number of atoms and
valence electrons, was termed by Langmuir (2) and de-
veloped further by Grimm (3), and later Erlenmeyer (4).
Friedmann (5) and Thornber (6) described bioisosterism
as a form of non-classical isosterism with relation to the
modulation of a biological endpoint. Since then, interest
and research on this concept have been gradually
increasing, and efforts have been put into collecting anec-
dotes of historically successful applications. Several exten-
sive reviews on examples for bioisosteric relations are
available (7–9), and a commercial solution captures
annotated data retrieved from primary literature (10).
Although these examples certainly contain valuable infor-
mation and are a great source of inspiration, from a prac-
tical point of view it is nevertheless questionable whether
success stories are truly generalizable, and what the
exhaustiveness of such lists is. We aim to improve on
both aspects in SwissBioisostere.
As modern drug discovery projects produce a wealth of
biochemical assay data for different chemical structures, it
is possible to mine these data computationally by frag-
menting the chemical structures and identifying pairs of
molecules that differ from each other only by small sub-
structural exchanges, i.e. the so-called matched molecular
pairs (MMPs) (11). The additional information of the dif-
ference in bioactivity in the biochemical assay allows
inferring the impact of this structural exchange.
The presented SwissBioisostere database contains such
molecular replacements annotated with their differences in
bioactivity against the primary target they were measured
against. This development has been made possible as
(i) extensive drug discovery data have been put in the
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public domain in a useable format by efforts such as
ChEMBL (12) and (ii) fast algorithms to mine these
data for MMPs have been developed (13,14). Due to
these recent developments, MMP analysis has gained
increased interest in the past years (15). Although histor-
ically, such analyses were almost exclusively possible
within the proprietary data of large pharmaceutical
companies and constrained to small data sets owing to
the algorithmic complexity, nowadays even very large
data sets can be analysed, and the increasing availability
of public domain databases (16) offers the potential to
perform these analyses also in academic settings.
With the SwissBioisostere database, we provide access
to a large knowledgebase of molecular replacements and
information on their observed impact on biological
activity, to aid medicinal chemists in their quest to
identify clinical candidates and to facilitate drug design
research via an interface that requires no speciﬁc training.
DATABASE CONSTRUCTION AND FEATURES
Experimental data retrieval and preparation
The ChEMBL database was used as primary data source
for experimental assay records. Version 13 (2012) was
downloaded from the website of the European
Bioinformatics Institute and held in a local MySQL
database. Then, data points of interest were selected ac-
cording to the following criteria: all compounds with
annotated assay data in IC50, EC50, Ki or Kd, which under-
went a standardization process by ChEMBL curators, were
selected. Bioactivity values were transformed into their
cologarithmic forms. Data points annotated with values
>10 mM, were kept, but ﬂagged as inactive. In case a
limiting operator (e.g. < or >) was attributed to an
activity, the corresponding data point was removed to
keep only clearly annotated bioactivity values.
Compounds with a molecular weight 1000Da were
ﬁltered to avoid long runtimes during the fragmentation
process. Assays were kept, if a curator of the ChEMBL
database annotated the observed effect as directly related
to an interaction with a particular molecularly deﬁned
target (conﬁdences level 8 and 9). Some assays were
manually removed owing to obvious errors in their
annotated bioactivity data. If more than one target was
attributed to a particular assay, all mentioned targets
were stored as target ensemble for this particular assay.
Target class tags were created by merging the tags of
levels 1 and 2 in the target classiﬁcation of the ChEMBL
database.
The resulting entries were grouped by their assay ID.
Members of such a group have been measured in the same
assay under equivalent conditions. Duplicate structures
were removed from each subset, and, in case their results
were annotated with differing experimental values,
replaced by the median. The compound structures were
standardized using the ‘Standardize Molecule’ component
in Pipeline Pilot (17) by de-salting, harmonizing the bonds
and formal charges of particular substructures [e.g. nitro
groups as N+(=O)O] and normalizing the chir-
ality annotation (18). Furthermore, compounds were
neutralized to the parent form by protonating acids and
deprotonating bases. Molecules containing bad valences
were ﬁltered out. Finally, a canonical tautomer was
deﬁned for each compound, based on the algorithm by
Sayle and Delaney (19).
For assays with more than one remaining compound, a
canonical SMILES was calculated for all compounds and
used together with information on assay ID, measured
bioactivity, corresponding target and target class as
input for the MMP identiﬁcation process.
The number of entries, compounds and assays ﬁltered
at each step are listed in Table 1. Figure 1 gives an
overview about the ﬁltering cascade.
MMP identiﬁcation
To identify pairs of molecules differing from each other
only by a small substructural exchange, the Hussain and
Rea algorithm (14) was implemented in Java using
libraries from the Chemistry Development Kit (20) and
the Indigo library from GGA (http://ggasoftware.com/
opensource/indigo). The algorithm fragments molecular
structures by cutting up to three bonds simultaneously
and stores one part of the molecule as key of a hash
table while the other part becomes the corresponding
object. For single cuts, in which only one bond is cut at
a time, both fragments become key and object, respect-
ively. For double and triple cuts, only the resulting frag-
ments with single attachment points become the key, and
scaffold (three attachment points) or linker (two attach-
ment points) becomes the object. If the fragmentation of
two different compounds results in equal keys, the two
corresponding objects deﬁne the variable part of an
identiﬁed MMP; i.e. a replacement has been found.
Cuttable bonds were deﬁned as single bonds that were
neither part of a ring system nor part of a functional
group such as, e.g. an amide group or a carboxylic
acid (SMARTS: [#6+0;!$(*=,#[!#6&!R])]!@!#!=[*]).
Furthermore, an additional rule was implemented, to be
able to detect replacements of groups connected by
exocyclic double bonds to a ring system (SMARTS:
[#6+0;R]=[#7&!R,#8&!R,#16&!R,#6+0&!R]). Replace-
ments are encoded as canonicalized SMIRKS. (21) Only
replacements with a maximal number of 12 heavy atoms
in the variable part were kept during the identiﬁcation
process. This threshold was set as a precautionary
measure with respect to the resulting number of potential
cuts and to ensure that replacements for larger scaffolds,
e.g. bicyclic ring systems, could still be identiﬁed.
Furthermore, the common part of a matched pair was
required to have at least the same number of heavy
atoms as the variable part. If compounds containing
marked stereo centres in the constant part were
matched, the match was veriﬁed for identical stereochem-
istry of all centres, and kept, if this was the case. Matches
of deﬁned stereo centres with non-annotated ones were
allowed, but ﬂagged in the database. Mismatched stereo
centres led to rejection of a previously found replacement.
Each performed fragmentation was validated by reconnec-
tion of the fragments and comparison with the original
molecule. Hydrogen replacements were identiﬁed in a
D1138 Nucleic Acids Research, 2013, Vol. 41, Database issue
separate step. An a posteriori ﬁlter was implemented for
replacements identiﬁed through triple cuts: Topological
distances between all attachment points were calculated
for both common parts of a replacement. In case the
sum of the differences in topological distance exceeded
the conservatively chosen threshold of 3, a triple cut
replacement was not accepted. This ﬁlter prevents the
occurrence of cases where the directionality of the
sidechains (the common constant part) between the two
fragments has signiﬁcantly changed, whereas at the same
time smaller changes (e.g. hexyl to pentyl or phenyl to
benzyl) remain accepted. Studies by Papadatos and
coworkers (22) showed the importance of the chemical
context of an attachment point when comparing difference
distributions of replacements observed in hERG, solubility
and lipohilicity assay data. Contextual information was
taken into account by annotating the corresponding attach-
ment points with such information during the fragmenta-
tion process. Three classes of attachment points were
deﬁned: (i) connection to an aromatic ring; (ii) link to an
aliphatic ring; and (iii) connection to an aliphatic linker.
A ﬁner differentiation like in the work of Papadatos has
been considered, but not been implemented because it
would have resulted in data subsets with only few
members, preventing a subsequent statistical assessment
of the impact of the chemical context. Furthermore, even
if it would be differentiated in a more detailed fashion (e.g.
between heteroaromatic rings containing atoms with poten-
tial H-bond acceptor and donor function), although
keeping an adequate amount of data, there might still be
an important difference in whether these atoms are located
in ortho-, meta- or para-position to the attachment point
for instance, which would prevent a relevant exploitation of
the data [see a corresponding example in the review article
of Griffen et al. (15)]. All calculated and accepted replace-
ments were stored in a MySQL 5.5 database.
SwissBioisostere database content
Currently (August 2012), SwissBioisostere contains infor-
mation on 5 586 462 unique replacements that can be
sub-divided into 33.03% Single Cuts (substituent replace-
ments), 45.89% Double Cuts (linker replacements) and
21.08% Triple Cuts (scaffold replacements). In total,
21 293 355 data points can be accessed via the interface.
Figure 2 highlights how often speciﬁc replacements have
been observed in the database. Indeed, about half of the
accessible replacements (46.61%) are singletons, i.e. have
been only observed once, 13.23% have been observed
ﬁve times. A list of the 1948 targets from 30 target
classes can be found in the Supplemental Material
(Supplementary Tables S1 and S2).
Table 2 gives an overview about the parameters stored
in the SwissBioisostere database and their origin.
Differences in logP, tPSA and Molecular Weight of the
fragments corresponding to a replacement are based on
values that have been provided by ChEMBL for the cor-
responding compounds. In case a replacement was
observed more than once, the mean of the differences
over all observed MMPs is reported.
To aid ranking of replacements, a scoring scheme has
been implemented. It is based on the observed bioactivity
differences of the replacement, its total count, as well as
the number of different targets, target classes and Murcko
scaffold families (23) in which it has been observed. For
more details on the implemented score, the reader is
referred to section 1 of the Supplemental Material.
We implemented an adapted version of the R group
descriptor published by Holliday et al. (24) as a chemical
similarity measure between fragments corresponding to a
replacement. Details on the calculation can be found in
section 2 of the Supplemental Material.
Figure 1. Overview of the different steps leading to the creation of the
SwissBioisostere database.
Table 1. Overview of the number of entries ﬁltered out during the different ﬁlter steps
Steps Entries Compounds Assays
ChEMBL v13 6 933 068 1 143 682 617 681
Entry selection 6 250 195 847 213 556 127
Removal of unwanted entries 60 840 14 219 20 070
Compound treatment 32 473 2462 632
MMP identiﬁcation 589 560 279 788 40 852
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Interface description
Access to the SwissBioisostere database is provided via a
web-based interface accessible at http://www.
swissbioisostere.ch. The starting page contains two
chemical sketchers and allows the user to perform two
different types of query: (i) query for observed replace-
ments of a particular substructure or (ii) query for a par-
ticular replacement. Scenario 1 is typically a question that
is raised if a New Chemical Entity drug discovery project
is running into an issue with a particular property and
aims to escape this situation by chemical modiﬁcation of
the lead compound. When entering a single substructure
into sketcher 1 on the start page of the website, the
database is searched for replacements that have been
used in the past for this exact substructure. An exemplary
screenshot (Figure 3) shows the results for the nitro
function. This page gives a broad overview of observed
replacements for this particular substructure. For more
details for a particular replacement, the user is able to
follow the links provided on each fragment. As medicinal
chemists are often interested in modifying lipophilicity
and/or polar surface area of a compound, these values
are reported in a dynamic plot, which allows to select on
the difference that a replacement would cause in these two
properties. The performance of each replacement in bio-
chemical assays as stored in the ChEMBL database is pre-
sented as a three-class distribution (improved, worsened
or isoactive). Class membership has been attributed with
regards to the observed change in bioactivity for a replace-
ment: improved ( bioactivity < 0.5 log units or trans-
formed inactive molecule to an active form), worsened
( bioactivity > 0.5 log units or transformed active
molecule to an inactive form) or isoactive (else). The
threshold of 0.5 log units, i.e. a factor of 3.2 in activity,
has been chosen to account for the unknown experimental
uncertainty in the underlying assays. It is possible to sort
the given replacements by values of the different param-
eters—tPSA, logP, MW, total count, class counts,
success-based score and chemical similarity measure—
provided in the table of results. Filtered results can then
be exported via a copy-to-clipboard function or to a CSV
ﬁle.
Via the link of a proposed replacement, or in case the
query was performed by adding two fragments in sketcher
1 and 2, respectively, the user obtains a detailed overview
page presenting data concerning the effects this particular
replacement showed experimentally with regards to the
activity against molecularly deﬁned targets. Figure 4
shows the results of the exchange of a pyridine with a
morpholine. The distribution of bioactivity differences is
visualized in two different manners: an overview of the full
distribution and a split by the chemical context of the at-
tachment points (in case of single and double cuts). The
plots are sensitive to a performed selection via the avail-
able ﬁlters. The column ﬁlter within the table provides the
user with options to ﬁlter for particular target classes,
targets or assay IDs. An additional ﬁlter box provides
the user with more possibilities to ﬁne-grain the data.
Here, it is possible to select the range of activity of
compound A of a matched pair A–B. Thereby, it is
possible to analyse, e.g. whether a replacement showed a
similar or improved bioactivity over the whole activity
range, or only in a particular region. Furthermore, the
data can be split to focus on results from different assay
types (functional or binding assays), according to the
conﬁdence the ChEMBL curators attributed to a particu-
lar assay/target annotation, or if only perfectly matched
stereochemistry or also MMPs, in which stereochemistry
was not completely deﬁned for one or both of the two
molecules, should be considered. The table of results
contains additional information on each measured data
point. Under each entry, representations of the
Table 2. Properties available in SwissBioisostere
Assays Compounds MMP Replacement
Assay IDa ChEMBL IDa Compound IDsa SMIRKSb
Targeta SMILESb Bioactivitiesa R group distanceb
Target classa ACD logPa Bioactivity differenceb Scoreb
Assay typea tPSAa Attachment point contextb
Conﬁdencea Molecular weighta Constant partb
PubMed IDa Murcko fragmentb Stereo tagb
aEntries were taken directly from ChEMBL.
bEntries are calculated properties for SwissBioisostere.
Figure 2. Information on counts of unique replacements stratiﬁed by
the type of cut that has been performed.
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corresponding molecules to a MMP can be retrieved, as
well as their measured bioactivity values in the biochem-
ical assay. Furthermore, a link to the respective website at
the European Bioinformatics Institute provides access to
the corresponding compound reports in the ChEMBL
database. Again, all ﬁltered results can be exported via a
copy to the clipboard function or download of a CSV ﬁle.
Applied technologies
In its current design, SwissBioisostere is built on Apache,
MySQL, Java, Javascript and Flash technologies. The
underlying RDBS is based on MySQL 5.5 (http://www
.mysql.com). The host server runs an Apache Tomcat 7
server (http://tomcat.apache.org). In the current version,
the molecular sketchers are based on MarvinSketch by
Chemaxon (http://www.chemaxon.com). All presented
plots are created using the ﬂot package developed by
Ole Laursen (http://code.google.com/p/ﬂot), result tables
and capabilities such as ranking, ﬁltering and exporting
data were implemented using the DataTables package by
SpryMedia (http://datatables.net). JQuery (http://jquery
.com) is the underlying javascript library that is accessed
by those components.
CONCLUSIONS AND FUTURE DIRECTIONS
To facilitate the identiﬁcation and assessment of molecu-
lar substructural replacements, we have developed and
released the SwissBioisostere database. Via a web
interface, accessible at http://www.swissbioisostere.ch,
Figure 3. Overview about the fragment replacement proposal process. The user enters a chemical substructure in sketcher 1 (1). The query results in
an overview page showing all replacements that have been performed for this particular substructure: (2) logP, tPSA overview that can be used to
select subsets, (3) results table, (4) image of performed replacement, which links to a detailed overview page, (5) bioactivity difference distribution,
three class classiﬁcation, (6) sorts columns, (7) data export.
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we provide medicinal chemists with a valuable idea gener-
ator that is supported by historical data and a platform to
aid research on individual molecular replacements. To
keep the database up to date with the latest information,
it is planned to perform updates at regular intervals. As
SwissBioisostere is one of the components of the online
tools developed by the Molecular Modelling group of the
Swiss Institute of Bioinformatics in Lausanne, we plan to
integrate a possibility to crosstalk with other web services
already available, e.g. SwissDock (25) (http://www
.swissdock.ch), or under development, to provide an
even better service to drug discovery researchers.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Sections 1 and 2, Supplementary Tables
1 and 2 and Supplementary References [26–29].
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